Biogen Idec (BIIB) soared nearly 10% to a new high Friday as its much-anticipated Alzheimer’s disease drug results surpassed Wall Street expectations. At a medical conference in France, Biogen reported the results of a phase 1b study in which 166 patients were divided into five groups, one a placebo group and the others taking different doses of Biogen’s drug candidate aducanumab, or BIIB-037. After 54 weeks, those in all but the lowest-dose group
Before the Q1 earnings reports start rolling in next month, likely the biggest mover of biotech and pharma stocks will be releases of clinical-trial data. Here are four such reports expected this month and what the Street expects from them. Probably the most anticipated is Biogen Idec’s (BIIB) presentation of phase one results on its Alzheimer’s disease drug BIIB-037 this Friday. Last week, RBC Capital Markets made the bull case for the drug,
A new research note from RBC Capital Markets offers a bullish take on Biogen Idec’s (BIIB) experimental drug for Alzheimer’s disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases. The conference, scheduled for March 18-22 in Nice, France, attracts medical and scientific professionals from across the globe. Biogen is expected to show “best in class” data for its BIIB037